...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental rheumatology >Infliximab treatment-induced formation of autoantibodies is common in Behcet's disease.
【24h】

Infliximab treatment-induced formation of autoantibodies is common in Behcet's disease.

机译：英夫利昔单抗治疗诱导的自身抗体形成在白塞病中很常见。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To study autoantibody formation in patients with Behcet's disease (BD) who received long-term treatment with the anti-TNF monoclonal antibody infliximab. METHODS: Serial sera from infliximab-treated patients (5 mg/kg at weeks 0, 4, 8, and every 6-8 weeks thereafter) were tested for various autoantibodies, using commercially available methods, at baseline and at 6 months (n = 20), at 12 months (n = 16), and at 18 months post-baseline (n = 12). Thirty-five age- and sex-matched BD patients, not treated with infliximab, served as controls. RESULTS: Autoantibodies were rarely seen in controls, as well as in infliximab treated patients at baseline. Formation of antinuclear antibodies (ANA) at low titers was evident in 13/20 (65%) patients at 6 months post-baseline; one additional patient developed anti-beta2 glycoprotein-I IgM antibodies (anti-beta(2)GPI). Of the 13 ANA-positive sera, low titers-IgM of anti-dsDNA or anti-beta(2)GPI were detected in 7 (35%) and 6 (30%) patients, respectively. Additional measurements at 12 and 18 months showed that the persistence and/or increasing titers of these autoantibodies depended on continuation of treatment. Antibodies to extractable nuclear antigens (anti-RNP, anti-SS-A/Ro, anti-SS-B/La, anti-Sm), rheumatoid factors, anti-cyclic citrullinated peptide antibodies and antineutrophil cytoplasmic antibodies, were never detected. No antibody-related symptoms, lupus-like disease, or thrombosis were observed in any patient up to 18 months of follow-up. CONCLUSION: Early induction of ANA and specific autoantibodies is common in BD patients treated with infliximab, including low titers of non-pathogenic anti-dsDNA and anti-Beta2GPI antibodies. A possible clinical significance of these findings needs to be documented in further studies, including more patients and longer follow-up periods.
机译：目的：研究长期接受抗TNF单克隆抗体英夫利昔单抗治疗的白塞病（BD）患者的自身抗体形成。方法：使用市售方法，在基线和6个月时，对接受英夫利昔单抗治疗的患者（在第0、4、8周以及此后每6-8周接受5 mg / kg血清）的各种自身抗体进行了测试（n = 20），基线12个月后（n = 16）和基线后18个月（n = 12）。 35例年龄和性别匹配的BD患者（未接受英夫利昔单抗治疗）作为对照。结果：在基线以及英夫利昔单抗治疗的患者中很少见到自身抗体。基线后6个月，在13/20（65％）患者中低滴度形成了抗核抗体（ANA）;另一名患者开发了抗β2糖蛋白I IgM抗体（抗β（2）GPI）。在13种ANA阳性血清中，分别在7（35％）和6（30％）患者中检测到抗dsDNA或抗beta（2）GPI的低滴度IgM。在12和18个月时进行的其他测量表明，这些自身抗体的持久性和/或滴度不断增加取决于治疗的持续性。从未检测到针对可提取核抗原的抗体（抗RNP，抗SS-A / Ro，抗SS-B / La，抗Sm），类风湿因子，抗环瓜氨酸肽抗体和抗中性粒细胞胞浆抗体。在长达18个月的随访中，未观察到任何与抗体相关的症状，狼疮样疾病或血栓形成。结论：在英夫利昔单抗治疗的BD患者中，ANA和特异性自身抗体的早期诱导很常见，包括低滴度的非致病性抗dsDNA抗体和抗Beta 2 GPI抗体。这些发现的可能的临床意义需要在进一步的研究中进行记录，包括更多的患者和更长的随访时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号